Related Experiment Video
Updated: Jul 17, 2025

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies
Published on: September 13, 2024
Transcriptomic and proteomic assessment of tocilizumab response in a randomized controlled trial of patients
Haridha Shivram1, Jason A Hackney1, Carrie M Rosenberger1
1Genentech, South San Francisco, CA 94080, USA.
Abstract:
High interleukin (IL)-6 levels are associated with greater COVID-19 severity. IL-6 receptor blockade by tocilizumab (anti-IL6R; Actemra) is used globally for the treatment of severe COVID-19, yet a molecular understanding of the therapeutic benefit remains unclear. We characterized the immune profile and identified cellular and molecular pathways modified by tocilizumab in peripheral blood samples from patients enrolled in the COVACTA study, a phase 3, randomized, double-blind, placebo-controlled trial of the efficacy and safety of tocilizumab in hospitalized patients with severe COVID-19. We identified markers of inflammation, lymphopenia, myeloid dysregulation, and organ injury that predict disease severity and clinical outcomes. Proteomic analysis confirmed a pharmacodynamic effect for tocilizumab and identified novel pharmacodynamic biomarkers. Transcriptomic analysis revealed that tocilizumab treatment leads to faster resolution of lymphopenia and myeloid dysregulation associated with severe COVID-19, indicating greater anti-inflammatory activity relative to placebo and potentially leading to faster recovery in patients hospitalized with COVID-19.
Related Concept Videos
Proteomics
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Clinical Trials
There are four phases in a clinical trial. A phase one...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Clinical Trials: Overview

